Cell therapy

#Cell therapy #Drug development #Drug discovery #Flow Cytometry #Guide

Advanced flow cytometry handbook

Are you missing out on the easier way to do flow cytometry? In this new handbook, Sartorius introduces the value of advanced flow cytometry, so every scientist feels empowered to run an experiment and analyse the data with confidence. This easy-to-use digital guide includes an introduction to the iQue® Advanced… Read More

#Intelligence #Resources

#BioIVT #Cell and gene therapy #Cell therapy #GMP #Manufacturing #Regulatory #Webinar

Webinar: Avoid unnecessary delays getting cell therapies to market

Both GTPs and GMPs must be followed to get cell-based advanced therapies or tissue-based therapy products to market. Learn about important considerations when sourcing Leukocytes/Cellular starting materials and related ancillary products that must be factored into your programme to efficiently move through the clinical pipeline and successfully receive regulatory approval. Read More

#News

Cell and gene therapies
#Advanced Therapies #Advanced Therapies Europe #Cell and gene therapy #Cell therapy #Gene therapy

Advanced Therapies Europe: From bench to bedside and boardroom

Advanced Therapies Europe took place from 9-12 September 2023 in Portugal. DDW’s Megan Thomas asked attendees: What is most important to scale from discovery to commercialisation of cell and gene therapies (CGTs)? Joel Eichmann, Co-Founder, Green Elephant Biotech It always comes down to time-to-market and risk minimisation. To cover these,… Read More

#Exclusive Content

#Biologics #CAR-T #Cell and gene therapy #Cell therapy #PCR #Whitepaper

Whitepaper on digital PCR for lentiviral vector characterisation

A new Whitepaper is available from Thermo Fisher Scientific, entitled ‘Lentiviral vector characterization for cell and gene therapy manufacturing using the QuantStudio Absolute Q Digital PCR System’. Recombinant lentiviral vectors are used for ex vivo transgene delivery in several gene-modified cell therapies, such as chimeric antigen receptor (CAR) T cell therapy. Read More

#News

#Biologics #CAR-T #Cell and gene therapy #Cell therapy #PCR

Explore the power of digital PCR for lentiviral vector characterisation

Recombinant lentiviral vectors are used for ex vivo transgene delivery in several gene-modified cell therapies, such as chimeric antigen receptor (CAR) T cell therapy. Reliable analytical methods such as digital PCR to characterise lentiviral vectors and the cells transduced with them are critical to helping ensure the safety and efficacy of… Read More

#Resources

CAR-T cells attack cancer cells
#Astellas Pharma #Cancer research #CAR-T #Cell therapy #Investment #Poseida Therapeutics #Solid tumours

Astellas invests in CAR-T cell therapy for solid tumours

Astellas Pharma will invest $50 million into Poseida Therapeutics to secure the rights to the company’s cancer CAR-T cell therapy for solid tumours, which is currently in Phase I trials. The total $50 million will include $25 million to acquire 8,333,333 shares of common stock of Poseida and a one-time… Read More

#Business & Investment #News

#Cancer research #Cell and Gene Therapy Catapult #Cell therapy #Funding #Innovate UK #NK:IO

£1.6m awarded to progress ovarian cancer cell therapy

NK:IO has been awarded £1.6m ($2.1m) in grant funding from Innovate UK’s New Cancer Therapeutics programme. The funding will support preclinical development, including development of a manufacturing process in collaboration with the Cell and Gene Therapy Catapult, whose mission is to support the UK’s cell and gene therapy industry. NK:IO… Read More

#Business & Investment #News

#Animal models #Cancer immunotherapy #Cell therapy #Covid-19 #Humanised Immune System (HIS) #Immunotherapy #Monoclonal antibodies #Mouse models #Oncology #Regulatory

Podcast: Immunotherapy, avelumab and the immunocompromised

This is the latest episode of the free DDW narrated podcast, “Immunotherapy, avelumab and protecting the immunocompromised”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Mice with humanised immune systems advance cell-based immunotherapy”, “… Read More

#News

Natural killer cells
#Cancer research #Cell therapy #EU patent #iPSC #Oncology #ONK Therapeutics

ONK secures European patent for CISH knockout in NK cells

The European Patent Office (EPO) has granted a licensed patent to ONK Therapeutics covering CISH knockout (KO) in natural killer (NK) cells, irrespective of the source of the NK cells. The patent includes human cord blood-derived, peripheral blood-derived, and NK cells derived from induced pluripotent stem… Read More

#Cancer Research #News

#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy

Under the microscope: Zoning in on the CGT sector

Listen to this article on the DDW Podcast: IB Communications’ CEO Michelle Boxall explains why there are two sides to the cell and gene therapy coin. Charles Dickens’ quote, “It was the best of times, it was the worst of times”, aptly describes the complexity surrounding CGT financing. With 2023’s financial… Read More

#Exclusive Content #Opinion

#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy

Understanding the future roadmaps of cell and gene therapy

Listen to this article on the DDW Podcast: DDW’s Megan Thomas caught up with George White, General Manager, Product Management, Cell & Gene Therapy at Cytiva, to learn more about the company’s insight into the CGT market. Key challenges for cell and gene therapies In order for cell and gene (CGT) therapies… Read More

#Exclusive Content #Opinion

#Advanced Therapies #CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

No sign of stopping: The rise of cell and gene therapy

Listen to this article on the DDW Podcast: Ryan Leahy, a science communication expert in cell and gene therapy, at Phacilitate, says there is a lot to celebrate but also much to assess, question and challenge in this sector. While the global economic landscape faces a major crisis and biotech is… Read More

#Exclusive Content #Opinion

CAR-T therapy
#Blood cancer #CAR-T #Cell therapy #Gilead Sciences #Kite Pharma #National Institute for Health and Care Excellence (NICE) #Oncology

UK’s NICE expands use of CAR-T cell therapy for blood cancer

The UK’s National Institute for Health and Care Excellence (NICE) has recommended additional uses for two CAR-T therapies from Gilead Sciences/Kite, as part of the Cancer Drugs Fund (CDF). Yescarta (axicabtagene ciloleucel: axi-cel) has been recommended by NICE for the treatment of eligible adult patients with diffuse large B cell… Read More

#News #Regulatory #Trending News

T cell attacking cancer cell
#Cancer immunotherapy #Cancer research #Cell therapy #Immunotherapy #Oncology #Personalised medicine #Webinar

The future of cancer immunotherapy: exclusive webinar

Hosted by DDW and supported by BPS BioScience and AcroBiosystems, ‘Cancer immunotherapy – where will the future opportunities be?’ will be free to attend on May 10 at 8AM PST | 11AM EST | 4PM BST | 5PM CET.   Join this free webinar to… Read More

Webinar date:
Brought to you by BPS BioScience and AcroBiosystems
#News